Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
PURPOSE: Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
ST Kim, JE Uhm, J Lee, J Sun, I Sohn, SW Kim… - Lung …, 2012 - lungcancerjournal.info
Purpose Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
[引用][C] Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
STAE KIM, JIEUN UHM, MJ AHN, J LEE… - Lung …, 2012 - pascal-francis.inist.fr
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small
cell lung cancer who failed previous chemotherapy CNRS Inist Pascal-Francis CNRS …
cell lung cancer who failed previous chemotherapy CNRS Inist Pascal-Francis CNRS …
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
ST Kim, JE Uhm, J Lee, JM Sun, I Sohn… - LUNG …, 2012 - scholarworks.bwise.kr
Purpose: Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
ST Kim, JE Uhm, J Lee, JM Sun, I Sohn… - Lung Cancer …, 2012 - europepmc.org
Purpose Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
ST Kim, JE Uhm, J Lee, J Sun… - Lung cancer …, 2012 - pubmed.ncbi.nlm.nih.gov
Purpose Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
ST Kim, JE Uhm, J Lee, J Sun, I Sohn, SW Kim… - Lung Cancer, 2012 - infona.pl
Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this randomized,
single-center, non-comparative phase II trial, the efficacy and safety of gefitinib and erlotinib …
single-center, non-comparative phase II trial, the efficacy and safety of gefitinib and erlotinib …
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
ST Kim, JE Uhm, J Lee, J Sun, I Sohn, SW Kim… - LUNG …, 2012 - scholar.korea.ac.kr
Purpose: Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
ST Kim, JE Uhm, J Lee, J mu Sun… - Lung …, 2012 - mdanderson.elsevierpure.com
Purpose: Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
[引用][C] Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
ST Kim, JE Uhm, J Lee, J Sun, I Sohn, SW Kim… - Lung Cancer, 2012 - cir.nii.ac.jp
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell
lung cancer who failed previous chemotherapy | CiNii Research CiNii 国立情報学研究所 学術 …
lung cancer who failed previous chemotherapy | CiNii Research CiNii 国立情報学研究所 学術 …